Arena Pharmaceuticals Announces Merck Discontinues Development Of Investigational Niacin Receptor Agonist Program For AtherosclerosisArena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merck also informed Arena that the company will not continue the collaboration...
Source: mnt.toPHT Corporation's Market Leading LogPad And StudyWorksTM EPRO Solutions Used In Sanofi Pasteur's Phase II Study Of New Clostridium Difficile VaccinePHT Corporation announced that Sanofi Pasteur is using PHT's LogPad® System and StudyWorksTM online portal for a Phase II trial to develop a vaccine against the Clostridium difficile bacterium. PHT is the leading provider of ePRO solutions used in pharmaceutical and biotechnology clinical trials worldwide...
Source: mnt.toLexiva (fosamprenavir calcium) - Dear Healthcare Professional Letter Potential association between Lexiva and myocardial infarction in HIV infected adults.
Source: www.fda.gov
# posted by Network @ 9:56 PM
